News and thoughts:

Microbial Cell, Vol. 3, No. 3, pp. 97 - 100; doi: 10.15698/mic2016.03.482

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization

Triana Amen1,2 and Daniel Kaganovich1

Download PDF download pdf
Show/hide additional information

    1 Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel.

    2 Alexander Grass Center for Bioengineering, Hebrew University of Jerusalem, Jerusalem, Israel.

Keywords: yeast, drug, FDA, Alzheimer’s, screen, amyloid beta.
Received originally: 03/02/2016 Received in revised form: 10/02/2016
Accepted: 11/02/2016 Published: 03/03/2016

Daniel Kaganovich, Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Triana Amen, Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel; Alexander Grass Center for Bioengineering, Hebrew University of Jerusalem, Jerusalem, Israel.

Conflict of interest statement: The authors declare no existing conflicts of interest.
Please cite this article as: Triana Amen and Daniel Kaganovich (2016). Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization. Microbial Cell 3(3): 97-100.

The older the average person alive today becomes, the more instances of neurodegeneration are observed world-wide. Alzheimer’s disease is the most common neurodegenerative disorder preferentially affecting older individuals with 26.6 million cases recorded in 2006. It is estimated that worldwide prevalence will rise to 100 million cases by 2050 [1]. There is currently no effective treatment nor preventative therapy for Alzheimer’s disease, and no definitive diagnosis besides post-mortem pathology. Diagnosis is based on the presence of intracellular inclusions of hyperphosphorylated microtubule associated protein tau and extracellular plaques consisting of amyloid beta (Aβ) peptide [2]. Aβ is a small peptide 40-42 aa in length, formed via amyloid precursor protein (APP) cleavage that results in Aβ release into the extracellular space. Aβ is normally observed circulating in the cerebrospinal fluid of mammals, and is produced mostly in the central nervous system [3]. Although Aβ aggregates are the major pathological hallmark of Alzheimer’s disease, the mechanisms of Aβ induced neurotoxicity is not well understood, and even less is known about the physiological function of Aβ peptide. Absence of APP results in embryonic development defects due to irregular migration of cerebral cortex neurons [4]. Recent work also indicates that Aβ peptide concentrations in the CNS modulate synaptic transmission and synaptic hyperactivity via direct binding to APP [5].

In addition to the pathological connection between Aβ deposition and Alzheimer’s, a genetic connection has been mapped as well. Multiple mutations in APP and its cleaving enzymes increase the risk of Alzheimer disease onset [6][7][8]. Some mutations alter the cleavage of APP, resulting in a shifted ratio of Aβ1-42 to Aβ1-40, thus increasing the proportion of the more aggregation-prone species. Other mutations affect the aggregation propensity of the Aβ1-40/42 peptide itself [9]. As with another aggregation-prone disease associated protein, α-synuclein in Parkinson’s disease, an increase in Aβ production results in its aggregation and the early onset of Alzheimer’s disease [10].

While most models of Aβ cellular pathology assume that toxicity stems from its aggregation propensity [11], there has been vigorous debate about whether the toxicity stems mostly from extracellular high-molecular weight amyloid plaques, or mostly from the low molecular weight oligomers [12][13][14]. Aβ can be re-incorporated into the cytoplasm after extra-cellular cleavage, and much evidence has accumulated over the past several years that favors the small intracellular oligomers as the toxic aggregate species [15]. Particularly convincing are seminal studies in simple models of disease: C. elegans and mice, demonstrating a link between aging, insulin signaling, and toxicity driven by low molecular weight oligomers of Aβ [16][17][18]. Another study, modeling Alzheimer’s disease in mice, showed that cognitive impairment precedes mature fibrillar deposits [19].

Due to the multifaceted and multifactorial nature of Alzheimer’s physiology, no single model can fully recapitulate disease. Mice are currently the model system that most closely resembles human beings while still being capable of exhibiting features of aging on a time-scale in line with the duration of a typical PhD or postdoc. Mice can also be scored for learning and memory defects, as well as motor neuron function. However, it is equally the case that a mouse that is artificially expressing extremely high amounts of Aβ in its brain will not accurately recapitulate the memory neuronal circuits of a 75-year-old human being. At the same time, mammalian models are sometimes less tractable and may offer less molecular and cellular detail of pathology and toxic events.

Simpler models of Aβ toxicity have been exploited with tremendous success towards greatly improving our understanding of the cellular pathology of molecular events associated with Alzheimer’s, as well as other neurodegenerative diseases. Of these, one of the most flexible, tractable, and versatile models has been the yeast Saccharomyces cerevisiae [20][21][22][23][24]. One of the things that make yeast such an important model for studying aggregation toxicity is that aggregation-prone, disease-associated proteins that would normally kill any mammalian cell are usually only mildly toxic in yeast. This suggests that yeast have efficient mechanisms for avoiding the aggregate toxicity that many human cells, and especially neurons, eventually succumb to. These mechanisms can be investigated in yeast with the hope of eventually exploiting them to address human pathology.

Another enormous advantage of yeast is the ease with which they can be used for high-throughput and high-content screening of genetic components of disease-associated molecular processes, as well as small molecule modulators of toxicity. Using a variety of high-throughput screening approaches several groups have identified genetic modifiers of α-synuclein toxicity [21][25], ALS-associated pathology [26], as well as Alzherimer’s-associated aggregation [27]. Similarly, a number of promising small molecular modifiers of Parkinson’s cellular pathology [20] have been discovered through yeast screening.

Recently, Park and colleagues working in Susan Liebman’s group discovered a number of small molecules capable of modulating Aβ aggregation in a yeast model [28]. The group constructed an Aβ fused to a translation factor domain to assess the Aβ oligomerization with a simple growth assay [29]. Park et al. screened 1200 FDA-approved drugs for the effect on Aβ oligomerization using a novel approach developed by the group earlier [28]. The study uncovered 7 well-known compounds able to reduce oligomerization and rescue cellular toxicity in yeast (Fig. 1). These molecules were then shown to alleviate the toxic effects of Aβ aggregation in cultured mammalian cells, partially validating the yeast screen hits.

Figure 1 Yeast provide novel insight into Alzheimer's disease

FIGURE 1: Yeast provide insight into molecular pathogenesis of Alzheimer disease and reveal modifiers of amyloid beta toxicity.

The molecules identified by the Liebman group show promise in that their molecular mechanism seems to involve modulating the small oligomers, thought to be the toxic species in the long chain of events leading to Aβ toxicity in the brain [28]. All of the molecules identified have already been approved by the FDA for use in humans, significantly accelerating any potential drug-to-market timeline. The next step would be a direct test in an animal model of Alzheimer’s disease. In a promising precedent, a previous study describing novel targets for Parkinson’s disease in yeast has already proven to rescue neurons [21], illustrating the similarity and conservation in cellular response to amyloid aggregation, and the nearly unlimited utility of budding yeast to humanity [30].


  1. R. Brookmeyer, E. Johnson, K. Ziegler‐Graham, and H.M. Arrighi, "Forecasting the global burden of Alzheimer's disease", Alzheimer's & Dementia, vol. 3, pp. 186-191, 2007.
  2. G.G. Glenner, C.W. Wong, V. Quaranta, and E.D. Eanes, "The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.", Applied pathology, 1984.
  3. R. Egensperger, S. Weggen, N. Ida, G. Multhaup, R. Schnabel, K. Beyreuther, and T.A. Bayer, "Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.", Acta neuropathologica, 1999.
  4. T.L. Young-Pearse, J. Bai, R. Chang, J.B. Zheng, J.J. LoTurco, and D.J. Selkoe, "A Critical Function for β-Amyloid Precursor Protein in Neuronal Migration Revealed byIn UteroRNA Interference", The Journal of Neuroscience, vol. 27, pp. 14459-14469, 2007.
  5. H. Fogel, S. Frere, O. Segev, S. Bharill, I. Shapira, N. Gazit, T. O’Malley, E. Slomowitz, Y. Berdichevsky, D. Walsh, E. Isacoff, J. Hirsch, and I. Slutsky, "APP Homodimers Transduce an Amyloid-β-Mediated Increase in Release Probability at Excitatory Synapses", Cell Reports, vol. 7, pp. 1560-1576, 2014.
  6. C. Haass, C.A. Lemere, A. Capell, M. Citron, P. Seubert, D. Schenk, L. Lannfelt, and D.J. Selkoe, "The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway", Nature Medicine, vol. 1, pp. 1291-1296, 1995.
  7. C. Nilsberth, A. Westlind-Danielsson, C.B. Eckman, M.M. Condron, K. Axelman, C. Forsell, C. Stenh, J. Luthman, D.B. Teplow, S.G. Younkin, J. Näslund, and L. Lannfelt, "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation", Nature Neuroscience, vol. 4, pp. 887-893, 2001.
  8. J.L. Jankowsky, D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, N.G. Copeland, M.K. Lee, L.H. Younkin, S.L. Wagner, S.G. Younkin, and D.R. Borchelt, "Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.", Human molecular genetics, 2003.
  9. O.I. Okereke, "Plasma β-Amyloid Level, Cognitive Reserve, and Cognitive Decline", JAMA, vol. 305, pp. 1655, 2011.
  10. A. Rovelet-Lecrux, D. Hannequin, G. Raux, N.L. Meur, A. Laquerrière, A. Vital, C. Dumanchin, S. Feuillette, A. Brice, M. Vercelletto, F. Dubas, T. Frebourg, and D. Campion, "APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy", Nature Genetics, vol. 38, pp. 24-26, 2005.
  11. R.J. O'Brien, and P.C. Wong, "Amyloid Precursor Protein Processing and Alzheimer's Disease", Annual Review of Neuroscience, vol. 34, pp. 185-204, 2011.
  12. R. Nagele, M. D’Andrea, W. Anderson, and H. Wang, "Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease", Neuroscience, vol. 110, pp. 199-211, 2002.
  13. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, and D.J. Selkoe, "Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.", Nature, 2002.
  14. J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, and K.H. Ashe, "Natural oligomers of the amyloid-β protein specifically disrupt cognitive function", Nature Neuroscience, vol. 8, pp. 79-84, 2004.
  15. D.M. Walsh, B.P. Tseng, R.E. Rydel, M.B. Podlisny, and D.J. Selkoe, "The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.", Biochemistry, 2000.
  16. E. Cohen, J. Bieschke, R.M. Perciavalle, J.W. Kelly, and A. Dillin, "Opposing Activities Protect Against Age-Onset Proteotoxicity", Science, vol. 313, pp. 1604-1610, 2006.
  17. E. Cohen, J.F. Paulsson, P. Blinder, T. Burstyn-Cohen, D. Du, G. Estepa, A. Adame, H.M. Pham, M. Holzenberger, J.W. Kelly, E. Masliah, and A. Dillin, "Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice", Cell, vol. 139, pp. 1157-1169, 2009.
  18. T. El‐Ami, L. Moll, F. Carvalhal Marques, Y. Volovik, H. Reuveni, and E. Cohen, "A novel inhibitor of the insulin/IGF signaling pathway protects from age‐onset, neurodegeneration‐linked proteotoxicity", Aging Cell, vol. 13, pp. 165-174, 2013.
  19. L. Mucke, and D.J. Selkoe, "Neurotoxicity of Amyloid  -Protein: Synaptic and Network Dysfunction", Cold Spring Harbor Perspectives in Medicine, vol. 2, pp. a006338-a006338, 2012.
  20. L.J. Su, P.K. Auluck, T.F. Outeiro, E. Yeger-Lotem, J.A. Kritzer, D.F. Tardiff, K.E. Strathearn, F. Liu, S. Cao, S. Hamamichi, K.J. Hill, K.A. Caldwell, G.W. Bell, E. Fraenkel, A.A. Cooper, G.A. Caldwell, J.M. McCaffery, J. Rochet, and S. Lindquist, "Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models", Disease Models & Mechanisms, vol. 3, pp. 194-208, 2010.
  21. D.F. Tardiff, N.T. Jui, V. Khurana, M.A. Tambe, M.L. Thompson, C.Y. Chung, H.B. Kamadurai, H.T. Kim, A.K. Lancaster, K.A. Caldwell, G.A. Caldwell, J. Rochet, S.L. Buchwald, and S. Lindquist, "Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in Neurons", Science, vol. 342, pp. 979-983, 2013.
  22. S. Tenreiro, M.M. Reimão-Pinto, P. Antas, J. Rino, D. Wawrzycka, D. Macedo, R. Rosado-Ramos, T. Amen, M. Waiss, F. Magalhães, A. Gomes, C.N. Santos, D. Kaganovich, and T.F. Outeiro, "Phosphorylation Modulates Clearance of Alpha-Synuclein Inclusions in a Yeast Model of Parkinson's Disease", PLoS Genetics, vol. 10, pp. e1004302, 2014.
  23. T.F. Outeiro, and S. Lindquist, "Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology", Science, vol. 302, pp. 1772-1775, 2003.
  24. M.D. Figley, and A.D. Gitler, "Yeast genetic screen reveals novel therapeutic strategy for ALS", Rare Diseases, vol. 1, pp. e24420, 2013.
  25. C.Y. Chung, V. Khurana, P.K. Auluck, D.F. Tardiff, J.R. Mazzulli, F. Soldner, V. Baru, Y. Lou, Y. Freyzon, S. Cho, A.E. Mungenast, J. Muffat, M. Mitalipova, M.D. Pluth, N.T. Jui, B. Schüle, S.J. Lippard, L. Tsai, D. Krainc, S.L. Buchwald, R. Jaenisch, and S. Lindquist, "Identification and Rescue of α-Synuclein Toxicity in Parkinson Patient–Derived Neurons", Science, vol. 342, pp. 983-987, 2013.
  26. Z. Sun, Z. Diaz, X. Fang, M.P. Hart, A. Chesi, J. Shorter, and A.D. Gitler, "Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.", PLoS biology, 2011.
  27. S. Treusch, S. Hamamichi, J.L. Goodman, K.E.S. Matlack, C.Y. Chung, V. Baru, J.M. Shulman, A. Parrado, B.J. Bevis, J.S. Valastyan, H. Han, M. Lindhagen-Persson, E.M. Reiman, D.A. Evans, D.A. Bennett, A. Olofsson, P.L. DeJager, R.E. Tanzi, K.A. Caldwell, G.A. Caldwell, and S. Lindquist, "Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast.", Science (New York, N.Y.), 2011.
  28. S. Park, K. Ratia, M. Ba, M. Valencik, and S. Liebman, "Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs", Microbial Cell, vol. 3, pp. 53-64, 2016.
  29. S. Bagriantsev, and S. Liebman, "Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system.", BMC biology, 2006.
  30. D. Kaganovich, R. Kopito, and J. Frydman, "Misfolded proteins partition between two distinct quality control compartments.", Nature, 2008.


© 2016

Creative Commons License
Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization by Amen and Kaganovich is licensed under a Creative Commons Attribution 4.0 International License.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.